Nanoparticle lung delivery and inhalation aerosols for targeted pulmonary nanomedicine

Nanomedicine in Drug Delivery

Volumn , Issue , 2013, Pages 43-74

  Mansour, Heidi M ^a,b   Park, Chun Woong ^c   Hayes, Don ^d,e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Chungbuk National University   (South Korea)

^d OHIO STATE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; COMPLIANCE CONTROL; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; MEDICAL NANOTECHNOLOGY; PROTEINS; PULMONARY DISEASES; RESPIRATORY SYSTEM;

ALVEOLAR EPITHELIUMS; DRUG DELIVERY SYSTEM; POORLY WATER-SOLUBLE DRUGS; SYSTEMIC DELIVERIES; TARGETED PULMONARY DELIVERIES; THERAPEUTIC APPLICATION; THERAPEUTIC PROTEIN; UNIFORM DISTRIBUTION;

TARGETED DRUG DELIVERY;

EID: 84875540628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14802     Document Type: Chapter

References (225)

1. Sung, J. C., Pulliam, B. L., and Edwards, D. A., Nanoparticles for drug delivery to the lungs, TRENDS in Biotechnology 25 (12), 563-570, 2007.
2. Bailey, M. M. and Berkland, C. J., Nanoparticle formulations in pulmonary drug delivery, Medicinal Research Reviews 29 (1), 196-212, 2009.
3. Mansour, H. M., Rhee, Y. S., and Wu, X., Nanomedicine in pulmonary delivery, International Journal of Nanomedicine 4, 299, 2009.
4. Kulkarni, V. S., Handbook of Non-Invasive Drug Delivery Systems: Science & Technology (Personal care & cosmetic technology series), Elsevier Inc, Burlington, MA, 2009.
5. Joshi, M. R. and Misra, A., Liposomal budesonide for dry powder inhaler: Preparation and stabilization, AAPS PharmSciTech 2 (4), 44, 2001.
6. Martin, T. M., Bandi, N., Shulz, R., Roberts, C. B., and Kompella, U. B., Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology, AAPS PharmSciTech 3 (3), 16-26, 2002.
7. El Gendy, N., Gorman, E. M., Munson, E. J., and Berkland, C., Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution, Journal of Pharmaceutical Sciences 98 (8), 2731-2746, 2009.
8. Jacobs, C. and Muller, R. H., Production and characterization of a budesonide nanosuspension for pulmonary administration, Pharmaceutical Research 19 (2), 189-194, 2002.
9. Shrewsbury, S. B., Bosco, A. P., and Uster, P. S., Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma, International Journal of Pharmaceutics 365 (1-2), 12-17, 2009.
10. Mezzena, M., Scalia, S., Young, P. M., and Traini, D., Solid lipid budesonide microparticles for controlled release inhalation therapy, The AAPS Journal 11 (4), 771-778, 2009.
11. Beck-Broichsitter, M., Gauss, J., Gessler, T., Seeger, W., Kissel, T., and Schmehl, T., Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles, Journal of Aerosol Medicine and Pulmonary Drug Delivery 23 (1), 47-57, 2010.
12. Kubavat, H., Shur, J., and Price, R., The influence of crystallization processes on the nano-mechanical properties of fluticasone propionate, Drug Delivery to the Lungs 22th Conference, Edinburgh, Scotland, UK. 10-12 December, 2011.
13. Doktorovova, S., Araujo, J., Garcia, M. L., Rakovsk ¥, E., and Souto, E. B., Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC), Colloids and Surfaces B: Biointerfaces 75 (2), 538-542, 2010.
14. Saari, S. M., Vidgren, M. T., Koskinen, M. O., Turjanmaa, V. M. H., Waldrep, J. C., and Nieminen, M. M., Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma, Chest 113 (6), 1573, 1998.
15. Wang, Z., Chen, J. F., Le, Y., Shen, Z. G., and Yun, J., Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation, Industrial & Engineering Chemistry Research 46 (14), 4839-4845, 2007.
16. Hyvonen, S., Peltonen, L., Karjalainen, M., and Hirvonen, J., Effect of nanoprecipitation on the physicochemical properties of low molecular weight poly (l-lactic acid) nanoparticles loaded with salbutamol sulphate and beclomethasone dipropionate, International Journal of Pharmaceutics 295 (1-2), 269-281, 2005.
17. Jaafar-Maalej, C., Andrieu, V., Elaissari, A., and Fessi, H., Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: Preparation, characterization and in vitro drug release, Journal of Nanoscience and Nanotechnology 11 (3), 1841-1851, 2011.
18. Ahmad, F. J., Mittal, G., Jain, G. K., Malhotra, G., Khar, R. K., and Bhatnagar, A., Nano-salbutamol dry powder inhalation: A new approach for treating broncho-constrictive conditions, European Journal of Pharmaceutics and Biopharmaceutics 71 (2), 282-291, 2009.
19. Hong, Y., Hu, F., and Yuan, H., Effect of PEG2000 on drug delivery characterization from solid lipid nanoparticles, Pharmazie 61 (4), 312-315, 2006.
20. Truong-Le, V. L., Walsh, S. M., Schweibert, E., Mao, H. Q., Guggino, W. B., August, J. T., and Leong, K. W., Gene transfer by DNA-gelatin nanospheres* 1, Archives of Biochemistry and Biophysics 361 (1), 47-56, 1999.
21. Sanders, N. N., De Smedt, S. C., Van Rompaey, E., Simoens, P., De Baets, F., and Demeester, J., Cystic fibrosis sputum. A barrier to the transport of nanospheres, American Journal of Respiratory and Critical Care Medicine 162 (5), 1905, 2000.
22. Changsan, N., Chan, H. K., Separovic, F., and Srichana, T., Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation, Journal of Pharmaceutical Sciences 98 (2), 628-639, 2009.
23. Ohashi, K., Kabasawa, T., Ozeki, T., and Okada, H., One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis, Journal of Controlled Release 135 (1), 19-24, 2009.
24. Pandey, R., Sharma, A., Zahoor, A., Sharma, S., Khuller, G., and Prasad, B., Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis, Journal of Antimicrobial Chemotherapy 52 (6), 981, 2003.
25. Shah, S. and Misra, A., Development of liposomal amphotericin B dry powder inhaler formulation, Drug Delivery 11 (4), 247-253, 2004.
26. Vyas, S. P., Quraishi, S., Gupta, S., and Jaganathan, K., Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages, International Journal of Pharmaceutics 296 (1-2), 12-25, 2005.
27. Yang, W., Johnston, K. P., and Williams III R. O., Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats, European Journal of Pharmaceutics and Biopharmaceutics 75 (1), 33-41, 2010.
28. Yang, W., Tam, J., Miller, D. A., Zhou, J., McConville, J. T., Johnston, K. P., and Williams III, R. O., High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers, International Journal of Pharmaceutics 361 (1-2), 177-188, 2008.
29. Omri, A., Beaulac, C., Bouhajib, M., Montplaisir, S., Sharkawi, M., and Lagace, J., Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa, Antimicrobial Agents and Chemotherapy 38 (5), 1090, 1994.
30. Pilcer, G., Vanderbist, F., and Amighi, K., Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery, International Journal of Pharmaceutics 365 (1-2), 162-169, 2009.
31. Finlay, W. and Wong, J., Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin, International Journal of Pharmaceutics 167 (1-2), 121-127, 1998.
32. Sweeney, L. G., Wang, Z., Loebenberg, R., Wong, J. P., Lange, C. F., and Finlay, W. H., Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery, International Journal of Pharmaceutics 305 (1-2), 180-185, 2005.
33. Conley, J., Yang, H., Wilson, T., Blasetti, K., Di Ninno, V., Schnell, G., and Wong, J. P., Aerosol delivery of liposome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice, Antimicrobial Agents and Chemotherapy 41 (6), 1288, 1997.
34. Zhao, H., Le, Y., Liu, H., Hu, T., Shen, Z., Yun, J., and Chen, J. F., Preparation of microsized spherical aggregates of ultrafine ciprofloxacin particles for dry powder inhalation (DPI), Powder Technology 194 (1-2), 81-86, 2009.
35. El-Gendy, N., Desai, V., and Berkland, C., Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols, Journal of Pharmaceutical Innovation 5 (3), 79-87, 2010.
36. Vila, A., Sanchez, A., Evora, C., Soriano, I., Vila Jato, J., and Alonso, M., PEG-PLA nanoparticles as carriers for nasal vaccine delivery, Journal of Aerosol Medicine 17 (2), 174-185, 2004.
37. Kumar, M., Kong, X., Behera, A. K., Hellermann, G. R., Lockey, R. F., and Mohapatra, S. S., Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma, Genetic Vaccines and Therapy 1 (3), 1-10, 2003.
38. Koshkina, N. V., Waldrep, J. C., Roberts, L. E., Golunski, E., Melton, S., and Knight, V., Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model, Clinical Cancer Research 7 (10), 3258, 2001.
39. Hureaux, J., Lagarce, F., Gagnadoux, F., Vecellio, L., Clavreul, A., Roger, E., Kempf, M., Racineux, J. L., Diot, P., and Benoit, J. P., Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxel, European Journal of Pharmaceutics and Biopharmaceutics 73 (2), 239-246, 2009.
40. Azarmi, S., Tao, X., Chen, H., Wang, Z., Finlay, W. H., Lobenberg, R., and Roa, W. H., Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles, International Journal of Pharmaceutics 319 (1-2), 155-161, 2006.
41. Gilbert, B. E., Knight, C., Alvarez, F. G., Waldrep, J. C., Rodarte, J. R., Knight, V., and Eschenbacher, W. L., Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol, American Journal of Respiratory and Critical Care Medicine 156 (6), 1789, 1997.
42. Letsou, G. V., Safi, H. J., Reardon, M. J., Ergenoglu, M., Li, Z., Klonaris, C. N., Baldwin, J. C., Gilbert, B. E., and Waldrep, J. C., Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression, The Annals of Thoracic Surgery 68 (6), 2044, 1999.
43. Zijlstra, G. S., Rijkeboer, M., Van Drooge, D. J., Sutter, M., Jiskoot, W., Van De Weert, M., Hinrichs, W. L. J., and Frijlink, H. W., Characterization of a cyclosporine solid dispersion for inhalation, The AAPS Journal 9 (2), 190-199, 2007.
44. Chougule, M., Padhi, B., and Misra, A., Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics, International Journal of Nanomedicine 2 (4), 675, 2007.
45. Sinswat, P., Overhoff, K. A., McConville, J. T., Johnston, K. P., and Williams III, R. O., Nebulization of nanoparticulate amorphous or crystalline tacrolimus-Single-dose pharmacokinetics study in mice, European Journal of Pharmaceutics and Biopharmaceutics 69 (3), 1057-1066, 2008.
46. Brigger, I., Dubernet, C., and Couvreur, P., Nanoparticles in cancer therapy and diagnosis, Advanced Drug Delivery Reviews 54 (5), 631-651, 2002.
47. Tiwari, S. B. and Amiji, M. M., A review of nanocarrier-based CNS delivery systems, Current Drug Delivery 3 (2), 219-232, 2006.
48. Kaur, I. P., Bhandari, R., Bhandari, S., and Kakkar, V., Potential of solid lipid nanoparticles in brain targeting, Journal of Controlled Release 127 (2), 97-109, 2008.
49. Davis, M. E., Nanoparticle therapeutics: An emerging treatment modality for cancer, Nature Reviews Drug Discovery 7 (9), 771-782, 2008.
50. ESF, Nanomedicine—An ESF-European Medical Research Councils (EMRC) Forward Look Report. Strasbourg cedex, France, 2004.
51. Webster, T. J., Nanomedicine: What’s in a definition?, International Journal of Nanomedicine 1 (2), 115, 2006.
52. NIH, N. I. o. H., National Institute of Health Roadmap for Medical Research: Nanomedicine, USA, 2006.
53. Torchilin, V. P., Lipid-core micelles for targeted drug delivery, Current Drug Delivery 2 (4), 319-327, 2005.
54. Florence, A. T., Pharmaceutical aspects of nanotechnology, in Chapter 12 in Modern Pharmaceutics, Volume 2: Applications and Advances, Florence, A. T. and Siepmann, J. (eds.), Informa Healthcare, New York, 2009.
55. Von Werne, T. and Patten, T. E., Preparation of structurally well-defined polymer-nanoparticle hybrids with controlled/living radical polymerizations, Journal of the American Chemical Society 121 (32), 7409-7410, 1999.
56. Pridgen, E. M., Langer, R., and Farokhzad, O. C., Biodegradable, polymeric nanoparticle delivery systems for cancer therapy, Nanomedicine 2 (5), 669-680, 2007.
57. Hussain, F., Hojjati, M., Okamoto, M., and Gorga, R. E., Review article: Polymer-matrix nanocomposites, processing, manufacturing, and application: An overview, Journal of Composite Materials 40 (17), 1511, 2006.
58. van Vlerken, L. E. and Amiji, M. M., Multi-functional polymeric nanoparticles for tumour-targeted drug delivery, 2006.
59. Almeida, A. J. and Souto, E., Solid lipid nanoparticles as a drug delivery system for peptides and proteins, Advanced Drug Delivery Reviews 59 (6), 478-490, 2007.
60. Joshi, M. D. and Muller, R. H., Lipid nanoparticles for parenteral delivery of actives, European Journal of Pharmaceutics and Biopharmaceutics 71 (2), 161-172, 2009.
61. Muchow, M., Maincent, P., and Muller, R. H., Lipid nanoparticles with a solid matrix (SLN¢ç, NLC¢ç, LDC¢ç) for oral drug delivery, Drug Development and Industrial Pharmacy 34 (12), 1394-1405, 2008.
62. MuEller, R. H., MaEder, K., and Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art, European Journal of Pharmaceutics and Biopharmaceutics 50 (1), 161-177, 2000.
63. Muller, R., Radtke, M., and Wissing, S., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Advanced Drug Delivery Reviews 54, S131-S155, 2002.
64. Pardeike, J., Hommoss, A., and Muller, R. H., Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products, International Journal of Pharmaceutics 366 (1-2), 170-184, 2009.
65. Schafer-Korting, M., Mehnert, W., and Korting, H. C., Lipid nanoparticles for improved topical application of drugs for skin diseases, Advanced drug Delivery Reviews 59 (6), 427-443, 2007.
66. Wissing, S., Kayser, O., and Muller, R., Solid lipid nanoparticles for parenteral drug delivery, Advanced Drug Delivery Reviews 56 (9), 1257-1272, 2004.
67. Crommelin, D. J. A. and Storm, G., Liposomes: From the bench to the bed, Journal of Liposome Research 13 (1), 33-36, 2003.
68. Metselaar, J. M., Mastrobattista, E., and Storm, G., Liposomes for intravenous drug targeting: Design and applications, Mini Reviews in Medicinal Chemistry 2 (4), 319-329, 2002.
69. Brandl, M., Liposomes as drug carriers: A technological approach, Biotechnology Annual Review 7, 59-85, 2001.
70. Lasic, D. D. and Martin, F., Stealth Liposomes, CRC Press, Boca Raton, FL, 1995.
71. Gregoriadis, G. and Florence, A. T., Liposomes in drug delivery, CRC Press, Boca Raton, FL, 1993.
72. Lawrence, M. J. and Rees, G. D., Microemulsion-based media as novel drug delivery systems, Advanced Drug Delivery Reviews 45 (1), 89-121, 2000.
73. Wu, W., Wang, Y., and Que, L., Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system, European Journal of Pharmaceutics and Biopharmaceutics 63 (3), 288-294, 2006.
74. Jadhav, K., Shaikh, I., Ambade, K., and Kadam, V., Applications of microemulsion based drug delivery system, Current Drug Delivery 3 (3), 267-273, 2006.
75. Hashida, M., Kawakami, S., and Yamashita, F., Lipid carrier systems for targeted drug and gene delivery, Chemical & Pharmaceutical Bulletin 53 (8), 871-880, 2005.
76. Davis, S. S., Washington, C., West, P., Illum, L., Liversidge, G., Sternson, L., and Kirsh, R., Lipid emulsions as drug delivery systems, Annals of the New York Academy of Sciences 507 (1), 75-88, 1987.
77. Collins-Gold, L., Lyons, R., and Bartholow, L., Parenteral emulsions for drug delivery, Advanced Drug Delivery Reviews 5 (3), 189-208, 1990.
78. Charman, W. N., Lipids, lipophilic drugs, and oral drug delivery—Some emerging concepts, Journal of Pharmaceutical Sciences 89 (8), 967-978, 2000.
79. Jamaty, C., Bailey, B., Larocque, A., Notebaert, E., Sanogo, K., and Chauny, J. M., Lipid emulsions in the treatment of acute poisoning: A systematic review of human and animal studies, Clinical Toxicology 48 (1), 1-27, 2010.
80. Pouton, C. W., Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and “self-microemulsifying” drug delivery systems, European Journal of Pharmaceutical Sciences 11, S93-S98, 2000.
81. Vinogradov, S. V., Colloidal microgels in drug delivery applications, Current Pharmaceutical Design 12 (36), 4703, 2006.
82. Vinogradov, S. V., Zeman, A. D., Batrakova, E. V., and Kabanov, A. V., Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs, Journal of Controlled Release 107 (1), 143-157, 2005.
83. Raemdonck, K., Demeester, J., and De Smedt, S., Advanced nanogel engineering for drug delivery, Soft Matter 5 (4), 707-715, 2008.
84. Kataoka, K., Harada, A., and Nagasaki, Y., Block copolymer micelles for drug delivery: Design, characterization and biological significance, Advanced Drug Delivery Reviews 47 (1), 113-131, 2001.
85. Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Guthi, J. S., Chin, S. F., Sherry, A. D., Boothman, D. A., and Gao, J., Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems, Nano Letters 6 (11), 2427-2430, 2006.
86. Maeda, H., Bharate, G., and Daruwalla, J., Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, European Journal of Pharmaceutics and Biopharmaceutics 71 (3), 409-419, 2009.
87. Cotes, J. E. and Leathart, G. L., Lung Function. Wiley Online Library, 1993.
88. Haverich, A., Scott, W., and Jamieson, S., Twenty years of lung preservation—A review, The Journal of Heart Transplantation 4 (2), 234, 1985.
89. Hickey, A. J. and Mansour, H. M., Delivery of drugs by the pulmonary route, in Modern Pharmaceutics, 5th ed., Florence, A. T. and Siepmann, J. (eds), Taylor & Francis, Inc., New York, 2009, pp. 191-219.
90. Weibel, E. R., Morphometry of the human lung, Anesthesiology 26 (3), 367, 1965.
91. Horsfield, K. and Woldenberg, M. J., Branching ratio and growth of tree-like structures, Respiration Physiology 63 (1), 97-107, 1986.
92. Pauwels, R., Newman, S., and Borgstrom, L., Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers, European Respiratory Journal 10 (9), 2127, 1997.
93. Yu, C. and Diu, C., A comparative study of aerosol deposition in different lung models, American Industrial Hygiene Association Journal 43 (1), 54-65, 1982.
94. Pich, J., Theory of gravitational deposition of particles from laminar flows in channels, Journal of Aerosol Science 3 (5), 351-361, 1972.
95. Ingham, D., Diffusion of aerosols from a stream flowing through a cylindrical tube, Journal of Aerosol Science 6 (2), 125-132, 1975.
96. Landahl, H., Particle removal by the respiratory system note on the removal of airborne particulates by the human respiratory tract with particular reference to the role of diffusion, Bulletin of Mathematical Biology 25 (1), 29-39, 1963.
97. Hinds, W. C., Aerosol technology: Properties, behavior, and measurement of airborne particles, Wiley-Interscience, New York, 1982.
98. Smola, M., Vandamme, T., and Sokolowski, A., Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases, International Journal of Nanomedicine 3 (1), 1, 2008.
99. Halbert, R., Natoli, J., Gano, A., Badamgarav, E., Buist, A., and Mannino, D., Global burden of COPD: Systematic review and meta-analysis, European Respiratory Journal 28 (3), 523, 2006.
100. Pison, U., Welte, T., Giersig, M., and Groneberg, D. A., Nanomedicine for respiratory diseases, European Journal of Pharmacology 533 (1-3), 341-350, 2006.
101. John, A. E., Lukacs, N. W., Berlin, A. A., Palecanda, A., Bargatze, R. F., Stoolman, L. M., and Nagy, J. O., Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease, The FASEB Journal 17 (15), 2296, 2003.
102. Rosenstein, B. J. and Zeitlin, P. L., Prognosis in cystic fibrosis, Current Opinion in Pulmonary Medicine 1 (6), 444, 1995.
103. Stern, R. C., The diagnosis of cystic fibrosis, The New England Journal of Medicine 336 (7), 487, 1997.
104. Groneberg, D., Eynott, P., Lim, S., Oates, T., Wu, R., Carlstedt, I., Roberts, P., McCann, B., Nicholson, A., and Harrison, B., Expression of respiratory mucins in fatal status asthmaticus and mild asthma, Histopathology 40 (4), 367-373, 2002.
105. Ramsey, B. W., Management of pulmonary disease in patients with cystic fibrosis, The New England Journal of Medicine 335 (3), 179, 1996.
106. Davies, J., Hovenberg, H., Linden, C., Howard, R., Richardson, P., Sheehan, J., and Carlstedt, I., Mucins in airway secretions from healthy and chronic bronchitic subjects, Biochemical Journal 313 (Pt 2), 431, 1996.
107. Gupta, R. and Jentoft, N., The structure of tracheobronchial mucins from cystic fibrosis and control patients, Journal of Biological Chemistry 267 (5), 3160, 1992.
108. Thornton, D. J., Sheehan, J. K., Lindgren, H., and Carlstedt, I., Mucus glycoproteins from cystic fibrotic sputum. Macromolecular properties and structural architecture, Biochemical Journal 276 (Pt 3), 667, 1991.
109. Thornton, D., Davies, J., Kraayenbrink, M., Richardson, P., Sheehan, J., and Carlstedt, I., Mucus glycoproteins from normal human tracheobronchial secretion, Biochemical Journal 265 (1), 179, 1990.
110. Sharma, P., Dudus, L., Nielsen, P. A., Clausen, H., Yankaskas, J. R., Hollingsworth, M. A., and Engelhardt, J. F., MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways, American Journal of Respiratory Cell and Molecular Biology 19 (1), 30-37, 1998.
111. Wickstrom, C., Davies, J., Eriksen, G., Veerman, E., and Carlstedt, I., MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: Identification of glycoforms and C-terminal cleavage, Biochemical Journal 334 (Pt 3), 685, 1998.
112. Flume, P. A., O’Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel Jr., P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., and Quittell, L., Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health, American Journal of Respiratory and Critical Care Medicine 176 (10), 957, 2007.
113. Cimmino, M., Nardone, M., Cavaliere, M., Plantulli, A., Sepe, A., Esposito, V., Mazzarella, G., and Raia, V., Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease, Archives of Otolaryngology Head and Neck Surgery 131 (12), 1097, 2005.
114. Koch, C. and Hiby, N., Pathogenesis of cystic fibrosis, Lancet 341 (8852), 1065, 1993.
115. Park, C. W., Hayes, D. J., and Mansour, H. M., Pulmonary inhalation aerosols for targeted antibiotics delivery, European Pharmaceutical Review 16 (1), 32-36, 2011.
116. Flume, P. and Klepser, M. E., The rationale for aerosolized antibiotics, Pharmacotherapy 22 (3 Part 2), 71-79, 2002.
117. Craig, W. A., Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men, Clinical Infectious Diseases 26 (1), 1-10, 1998.
118. FitzSimmons, S. C., The changing epidemiology of cystic fibrosis, The Journal of Pediatrics 122 (1), 1-9, 1993.
119. Beringer, P. M., New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis, Current Opinion in Pulmonary Medicine 5 (6), 371, 1999.
120. Geller, D. E., Aerosol antibiotics in cystic fibrosis, Respiratory Care 54 (5), 658-670, 2009.
121. Yang, Y., Tsifansky, M. D., Wu, C. J., Yang, H. I., Schmidt, G., and Yeo, Y., Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis, Pharmaceutical Research 27 (1), 151-160, 2010.
122. Cheow, W. S., Chang, M. W., and Hadinoto, K., Antibacterial efficacy of inhalable antibiotic-encapsulated biodegradable polymeric nanoparticles against E. coli biofilm cells, Journal of Biomedical Nanotechnology 6 (4), 391-403, 2010.
123. Kwon, G. S., Polymeric micelles for delivery of poorly water-soluble compounds, Critical Reviews in Therapeutic Drug Carrier Systems 20 (5), 357-403, 2003.
124. Nishiyama, N. and Kataoka, K., Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery, Pharmacology & Therapeutics 112 (3), 630-648, 2006.
125. Jones, M. C. and Leroux, J. C., Polymeric micelles-a new generation of colloidal drug carriers, European Journal of Pharmaceutics and Biopharmaceutics 48 (2), 101-111, 1999.
126. Marsh, D., Bartucci, R., and Sportelli, L., Lipid membranes with grafted polymers: Physicochemical aspects, Biochimica et Biophysica Acta (BBA)-Biomembranes 1615 (1-2), 33-59, 2003.
127. Gaber, N. N., Darwis, Y., Peh, K. K., and Tan, Y. T. F., Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate, Journal of Nanoscience and Nanotechnology, 69 (10), 3095-3101, 2006.
128. Chao, Y. C., Chang, S. F., Lu, S. C., Hwang, T. C., Hsieh, W. H., and Liaw, J., Ethanol enhanced in vivo gene delivery with non-ionic polymeric micelles inhalation, Journal of Controlled Release 118 (1), 105-117, 2007.
129. Yang, Y. T., Chen, C. T., Yang, J. C., and Tsai, T., Spray-dried microparticles containing polymeric micelles encapsulating hematoporphyrin, The AAPS Journal 12 (2), 138-146, 2010.
130. Mansour, H. M., Sohn, M., Al-Ghananeem, A., and DeLuca, P. P., Materials for pharmaceutical dosage forms: Molecular pharmaceutics and controlled release drug delivery aspects. Invited Paper. International Journal of Molecular Sciences: Special Issue-Material Sciences and Nanotechnology Section—Biodegradability of Materials, 11, 3298-3322, 2010.
131. Houchin, M. and Topp, E., Chemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms, Journal of Pharmaceutical Sciences 97 (7), 2395-2404, 2008.
132. Na, D. H. and DeLuca, P. P., PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly (D, L-lactide-co-glycolide), Pharmaceutical Research 22 (5), 736-742, 2005.
133. Na, D. H., Lee, K. C., and DeLuca, P. P., PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics, Pharmaceutical Research 22 (5), 743-749, 2005.
134. Kumar, R. and Majeti, N., A review of chitin and chitosan applications, Reactive and Functional Polymers 46 (1), 1-27, 2000.
135. Wei, L., Cai, C., Lin, J., and Chen, T., Dual-drug delivery system based on hydrogel/micelle composites, Biomaterials 30 (13), 2606-2613, 2009.
136. Smidsrd, O. and Skjaok-Brk, G., Alginate as immobilization matrix for cells, Trends in Biotechnology 8, 71-78, 1990.
137. Rowley, J. A., Madlambayan, G., and Mooney, D. J., Alginate hydrogels as synthetic extracellular matrix materials, Biomaterials 20 (1), 45-53, 1999.
138. Liao, Y. H., Jones, S. A., Forbes, B., Martin, G. P., and Brown, M. B., Hyaluronan: Pharmaceutical characterization and drug delivery, Drug Delivery 12 (6), 327-342, 2005.
139. Malafaya, P. B., Silva, G. A., and Reis, R. L., Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications, Advanced Drug Delivery Reviews 59 (4-5), 207-233, 2007.
140. Friess, W., Collagen-biomaterial for drug delivery1, European Journal of Pharmaceutics and Biopharmaceutics 45 (2), 113-136, 1998.
141. Schoof, H., Apel, J., Heschel, I., and Rau, G., Control of pore structure and size in freeze dried collagen sponges, Journal of Biomedical Materials Research 58 (4), 352-357, 2001.
142. Kojima, C., Tsumura, S., Harada, A., and Kono, K., A collagen-mimic dendrimer capable of controlled release, Journal of the American Chemical Society 131 (17), 6052-6053, 2009.
143. Tseng, C. L., Su, W. Y., Yen, K. C., Yang, K. C., and Lin, F. H., The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation, Biomaterials 30 (20), 3476-3485, 2009.
144. Seong, J. H., Lee, K. M., Kim, S. T., Jin, S. E., and Kim, C. K., Polyethylenimine based antisense oligodeoxynucleotides of IL 4 suppress the production of IL 4 in a murine model of airway inflammation, The Journal of Gene Medicine 8 (3), 314-323, 2006.
145. Wernig, K., Griesbacher, M., Andreae, F., Hajos, F., Wagner, J., Mosgoeller, W., and Zimmer, A., Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles, Journal of Controlled Release 130 (2), 192-198, 2008.
146. Zahoor, A., Sharma, S., and Khuller, G., Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis, International Journal of Antimicrobial Agents 26 (4), 298-303, 2005.
147. Kimura, S., Egashira, K., Chen, L., Nakano, K., Iwata, E., Miyagawa, M., Tsujimoto, H., Hara, K., Morishita, R., and Sueishi, K., Nanoparticle-mediated delivery of nuclear factor {kappa} B decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension, Hypertension 53 (5), 877, 2009.
148. Beck-Broichsitter, M., Schmehl, T., Seeger, W., and Gessler, T., Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models, Journal of Nanomaterials 2011, 1-16, 2011.
149. Densmore, C. L., Advances in noninvasive pulmonary gene therapy, Current Drug Delivery 3 (1), 55-63, 2006.
150. De Smedt, S. C., Demeester, J., and Hennink, W. E., Cationic polymer based gene delivery systems, Pharmaceutical Research 17 (2), 113-126, 2000.
151. Ogris, M. and Wagner, E., Tumor-targeted gene transfer with DNA polyplexes, Somatic Cell and Molecular Genetics 27 (1), 85-95, 2002.
152. Rudolph, C., Schillinger, U., Plank, C., Gessner, A., Nicklaus, P., Muller, R., and Rosenecker, J., Nonviral gene delivery to the lung with copolymer-protected and transferrin-modified polyethylenimine, Biochimica et Biophysica Acta (BBA)-General Subjects 1573 (1), 75-83, 2002.
153. Eliyahu, H., Joseph, A., Schillemans, J., Azzam, T., Domb, A., and Barenholz, Y., Characterization and in vivo performance of dextran-spermine polyplexes and DOTAP/cholesterol lipoplexes administered locally and systemically, Biomaterials 28 (14), 2339-2349, 2007.
154. Chono, S., Li, S. D., Conwell, C. C., and Huang, L., An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor, Journal of Controlled Release 131 (1), 64-69, 2008.
155. Ko, Y. T., Kale, A., Hartner, W. C., Papahadjopoulos-Sternberg, B., and Torchilin, V. P., Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery, Journal of Controlled Release 133 (2), 132-138, 2009.
156. Ungaro, F., d’Emmanuele di Villa Bianca, R., Giovino, C., Miro, A., Sorrentino, R., Quaglia, F., and La Rotonda, M. I., Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs, Journal of Controlled Release 135 (1), 25-34, 2009.
157. Dailey, L., Kleemann, E., Wittmar, M., Gessler, T., Schmehl, T., Roberts, C., Seeger, W., and Kissel, T., Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA, Pharmaceutical Research 20 (12), 2011-2020, 2003.
158. Yamamoto, H., Hoshina, W., Kurashima, H., Takeuchi, H., Kawashima, Y., Yokoyama, T., and Tsujimoto, H., Engineering of poly (DL-lactic-co-glycolic acid) nano-composite particle for dry powder inhalation dosage forms of insulin with spray fluidized bed Granulating system, Journal of the Society of Powder Technology, Japan 41, 514-521, 2004.
159. Muller, R. H., Mader, K., and Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art, European Journal of Pharmaceutics and Biopharmaceutics 50 (1), 161-177, 2000.
160. Siekmann, B. and Westesen, K., Sub-micron sized parenteral carrier systems based on solid lipids, Pharmaceutical and Pharmacological Letters 1, 123-126, 1992.
161. Muchow, M., Maincent, P., and Muller, R. H., Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery, Drug Development and Industrial Pharmacy 34 (12), 1394-1405, 2008.
162. Joshi, M. D. and Muller, R. H., Lipid nanoparticles for parenteral delivery of actives, European Journal of Pharmaceutics and Biopharmaceutics 71 (2), 161-172, 2009.
163. Mehnert, W. and Mader, K., Solid lipid nanoparticles: Production, characterization and applications, Advanced Drug Delivery Reviews 47 (2-3), 165-196, 2001.
164. Mansour, H. M., Rhee, Y. S., Park, C. W., and DeLuca, P. P., Lipid nanoparticulate drug delivery and nanomedicine, in Lipids in Nanotechnology, First ed., Moghis, A. American Oil Chemists Society (AOCS) Press, Urbana, Illinois, 2011, pp. 221-268.
165. Muller, R. H., Ruhl, D., Runge, S., Schulze-Forster, K., and Mehnert, W., Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant, Pharmaceutical Research 14 (4), 458-462, 1997.
166. Heydenreich, A., Westmeier, R., Pedersen, N., Poulsen, H., and Kristensen, H., Preparation and purification of cationic solid lipid nanospheres—Effects on particle size, physical stability and cell toxicity, International Journal of Pharmaceutics 254 (1), 83-87, 2003.
167. Pandey, R. and Khuller, G., Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis, Tuberculosis 85 (4), 227-234, 2005.
168. Koshkina, N., Waldrep, J., and Knight, V., Camptothecins and lung cancer: Improved delivery systems by aerosol, Current Cancer Drug Targets 3 (4), 251-264, 2003.
169. Hu, L., Jia, Y., and WenDing, Preparation and characterization of solid lipid nanoparticles loaded with epirubicin for pulmonary delivery, Pharmazie 65 (8), 585-587, 2010.
170. Liu, J., Gong, T., Fu, H., Wang, C., Wang, X., Chen, Q., Zhang, Q., He, Q., and Zhang, Z., Solid lipid nanoparticles for pulmonary delivery of insulin, International Journal of Pharmaceutics 356 (1-2), 333-344, 2008.
171. Rudolph, C., Schillinger, U., Ortiz, A., Tabatt, K., Plank, C., Muller, R. H., and Rosenecker, J., Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo, Pharmaceutical Research 21 (9), 1662-1669, 2004.
172. Videira, M., Gano, L., Santos, C., Neves, M., and Almeida, A., Lymphatic uptake of lipid nanoparticles following endotracheal administration, Journal of Microencapsulation 23 (8), 855-862, 2006.
173. Videira, M. A., Botelho, M., Santos, A. C., Gouveia, L. F., Pedroso de Lima, J., and Almeida, A. J., Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles, Journal of Drug Targeting 10 (8), 607-613, 2002.
174. Gershkovich, P., Wasan, K. M., and Barta, C. A., A review of the application of lipid-based systems in systemic, dermal/transdermal, and ocular drug delivery, Critical Reviews in Therapeutic Drug Carrier Systems 25 (6), 545, 2008.
175. El Maghraby, G., Barry, B., and Williams, A., Liposomes and skin: From drug delivery to model membranes, European Journal of Pharmaceutical Sciences 34 (4-5), 203-222, 2008.
176. Mansour, H. M. and Zografi, G., The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions, Journal of Pharmaceutical Sciences 96 (2), 377-396, 2007.
177. Mansour, H. M. and Zografi, G., Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface, Langmuir: The ACS Journal of Surfaces and Colloids 23 (7), 3809-3819, 2007.
178. Mansour, H. M., Damodaran, S., and Zografi, G., Characterization of the in situ structural and interfacial properties of the cationic hydrophobic heteropolypeptide, KL4, in lung surfactant bilayer and monolayer models at the air-water interface: Implications for pulmonary surfactant delivery, Molecular Pharmaceutics 5 (5), 681-695, 2008.
179. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., and Barenholz, Y., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Research 54 (4), 987, 1994.
180. Martin, F. J. and Papahadjopoulos, D., Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting, Journal of Biological Chemistry 257 (1), 286, 1982.
181. Torchilin, V. P., Recent advances with liposomes as pharmaceutical carriers, Nature Reviews Drug Discovery 4 (2), 145-160, 2005.
182. Klibanov, A. L., Maruyama, K., Torchilin, V. P., and Huang, L., Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Letters 268 (1), 235-237, 1990.
183. Blume, G. and Cevc, G., Molecular mechanism of the lipid vesicle longevity in vivo, Biochimica et Biophysica Acta (BBA)-Biomembranes 1146 (2), 157-168, 1993.
184. Wu, X. and Mansour, H. M., Nanopharmaceuticals II: Application of nanoparticles and nanocarrier systems in pharmaceutics and nanomedicine, International Journal of Nanotechnology 8 (1), 115-145, 2011.
185. Storm, G., Belliot, S. O., Daemen, T., and Lasic, D. D., Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system, Advanced Drug Delivery Reviews 17 (1), 31-48, 1995.
186. Storm, G. and Crommelin, D. J. A., Liposomes: Quo vadis?, Pharmaceutical Science & Technology Today 1 (1), 19-31, 1998.
187. Felgner, P. L. and Ringold, G., Cationic liposome-mediated transfection, Nature 337 (6205), 387-388, 1989.
188. Rhee, Y. S. and Mansour, H. M., Nanopharmaceuticals I: Nanocarrier systems in drug delivery, International Journal of Nanotechnology 8 (1), 84-114, 2011.
189. Willis, L., Hayes, D. J., and Mansour, H. M., Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery, Lung 190 (3), 251-262, 2012.
190. Courrier, H., Butz, N., and Vandamme, T. F., Pulmonary drug delivery systems: Recent developments and prospects, Critical Reviews in Therapeutic Drug Carrier Systems 19 (4-5), 425-498, 2002.
191. Niven, R. W., Delivery of biotherapeutics by inhalation aerosol, Critical Reviews in Therapeutic Drug Carrier Systems 12 (2-3), 151, 1995.
192. Darwis, Y. and Kellaway, I., Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes, International Journal of Pharmaceutics 215 (1-2), 113-121, 2001.
193. Wijagkanalan, W., Higuchi, Y., Kawakami, S., Teshima, M., Sasaki, H., and Hashida, M., Enhanced anti-inflammation of inhaled dexamethasone palmitate using mannosylated liposomes in an endotoxin-induced lung inflammation model, Molecular Pharmacology 74 (5), 1183, 2008.
194. Bi, R., Shao, W., Wang, Q., and Zhang, N., Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery, Journal of Drug Targeting 16 (9), 639-648, 2008.
195. Behr, J., Zimmermann, G., Baumgartner, R., Leuchte, H., Neurohr, C., Brand, P., Herpich, C., Sommerer, K., Seitz, J., and Menges, G., Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation, Journal of Aerosol Medicine and Pulmonary Drug Delivery 22 (2), 121-130, 2009.
196. Hickey, A. J. and Mansour, H. M., Volume 2: Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols, in Modified-Release Drug Delivery Technology 2nd ed., Rathbone, M. J., Hadgraft, J., Roberts, M. S., and Lane, M. E. Informa Healthcare, New York, 2008, pp. 573-602.
197. Bilgili, E., Hamey, R., and Scarlett, B., Nano-milling of pigment agglomerates using a wet stirred media mill: Elucidation of the kinetics and breakage mechanisms, Chemical Engineering Science 61 (1), 149-157, 2006.
198. Robinson, G. M., Jackson, M. J., and Whitfield, M. D., A review of machining theory and tool wear with a view to developing micro and nano machining processes, Journal of Materials Science 42 (6), 2002-2015, 2007.
199. Zhang, J., Wu, L., Chan, H. K., and Watanabe, W., Formation, characterization, and fate of inhaled drug nanoparticles, Advanced Drug Delivery Reviews, 63 (6), 441-455, 2011.
200. Li, X. and Mansour, H. M., Physicochemical characterization and water vapor absorption of organic solution advanced spray dried trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery, AAPS PharmSciTech: Special Theme: Advances in Pharmaceutical Excipients Research and Use: Novel Materials, Functionalities and Testing 12 (4), 1420-1430, 2011.
201. Rogers, T. L., Johnston, K. P., and Williams III R. O., Solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies, Drug Development and Industrial Pharmacy 27 (10), 1003-1015, 2001.
202. Subramaniam, B., Rajewski, R. A., and Snavely, K., Pharmaceutical processing with supercritical carbon dioxide, Journal of Pharmaceutical Sciences 86 (8), 885-890, 1997.
203. Shekunov, B. Y., Chattopadhyay, P., Seitzinger, J., and Huff, R., Nanoparticles of poorly water-soluble drugs prepared by supercritical fluid extraction of emulsions, Pharmaceutical Research 23 (1), 196-204, 2006.
204. Chattopadhyay, P., Huff, R., and Shekunov, B., Drug encapsulation using supercritical fluid extraction of emulsions, Journal of Pharmaceutical Sciences 95 (3), 667-679, 2006.
205. Hickey, A. J., Mansour, H. M., Telko, M. J., Xu, Z., Smyth, H. D. C., Mulder, T., McLean, R., Langridge, J., and Papadopoulos, D., Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics, Journal of Pharmaceutical Sciences 96 (5), 1282-1301, 2007.
206. Wu, X., Li, X., and Mansour, H. M., Surface analytical techniques in solid-state particle characterization: Implications for predicting performance in dry powder inhalers. Invited Paper, KONA Powder & Particle Journal 28, 3-19, 2010.
207. Park, C. W., Rhee, Y. S., Vogt, F., Hayes, D. J., Zwischenberger, J. B., DeLuca, P. P., and Mansour, H. M., Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex-vivo in respiratory drug delivery. Invited Paper., Advanced Drug Delivery Reviews 64 ((4) Special Theme Issue-Computational and Visualization Approaches in Respiratory Delivery.), 344-356, 2012.
208. Kwong, W. T. J., Ho, S. L., and Coates, A. L., Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor, Journal of Aerosol Medicine 13 (4), 303-314, 2000.
209. Thompson, P. J., Drug delivery to the small airways, American Journal of Respiratory and Critical Care Medicine 157 (5), S199, 1998.
210. Sardar, S. B., Philip, M., Mayo, P. R., and Sioutas, C., Size-fractionated measurements of ambient ultrafine particle chemical composition in Los Angeles using the NanoMOUDI, Environmental Science & Technology 39 (4), 932-944, 2005.
211. Lin, C. C., Chen, S. J., Huang, K. L., Hwang, W. I., Chang-Chien, G. P., and Lin, W. Y., Characteristics of metals in nano/ultrafine/fine/coarse particles collected beside a heavily trafficked road, Environmental Science & Technology 39 (21), 8113-8122, 2005.
212. Venkatachari, P., Hopke, P. K., Brune, W. H., Ren, X., Lesher, R., Mao, J., and Mitchell, M., Characterization of wintertime reactive oxygen species concentrations in Flushing, New York, Aerosol Science and Technology 41 (2), 97-111, 2007.
213. Geller, M. D., Kim, S., Misra, C., Sioutas, C., Olson, B. A., and Marple, V. A., A methodology for measuring size-dependent chemical composition of ultrafine particles, Aerosol Science and Technology 36 (6), 748-762, 2002.
214. Bunker, M., Davies, M., and Roberts, C., Towards screening of inhalation formulations: Measuring interactions with atomic force microscopy, Expert Opinion on Drug Delivery, 2 (4), 613-624, 2005.
215. Zhu, X., Birringer, R., Herr, U., and Gleiter, H., X-ray diffraction studies of the structure of nanometer-sized crystalline materials, Physical Review B 35 (17), 9085, 1987.
216. Nagvekar, A. A., Trickler, W. J., and Dash, A. K., Current analytical methods used in the in vitro evaluation of nano-drug delivery systems, Current Pharmaceutical Analysis 5 (4), 358-366, 2009.
217. Saleki-Gerhardt, A., Ahlneck, C., and Zografi, G., Assessment of disorder in crystalline solids, International Journal of Pharmaceutics 101 (3), 237-247, 1994.
218. Steimer, A., Haltner, E., and Lehr, C. M., Cell culture models of the respiratory tract relevant to pulmonary drug delivery, Journal of Aerosol Medicine 18 (2), 137-182, 2005.
219. Borchard, G., Cassara, M. L., Roemele, P. E. H., Florea, B. I., and Junginger, H. E., Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu 3), Journal of Pharmaceutical Sciences 91 (6), 1561-1567, 2002.
220. Ehrhardt, C., Fiegel, J., Fuchs, S., Abu-Dahab, R., Schaefer, U., Hanes, J., and Lehr, C. M., Drug absorption by the respiratory mucosa: Cell culture models and particulate drug carriers, Journal of Aerosol Medicine 15 (2), 131-139, 2002.
221. Foster, K. A., Avery, M. L., Yazdanian, M., and Audus, K. L., Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery, International Journal of Pharmaceutics 208 (1-2), 1-11, 2000.
222. Foster, K. A., Oster, C. G., Mayer, M. M., Avery, M. L., and Audus, K. L., Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism, Experimental Cell Research 243 (2), 359-366, 1998.
223. Manford, F., Tronde, A., Jeppsson, A. B., Patel, N., Johansson, F., and Forbes, B., Drug permeability in 16HBE14o-airway cell layers correlates with absorption from the isolated perfused rat lung, European Journal of Pharmaceutical Sciences 26 (5), 414-420, 2005.
224. Vaughn, J. M., McConville, J. T., Burgess, D., Peters, J. I., Johnston, K. P., Talbert, R. L., and Williams III, R. O., Single dose and multiple dose studies of itraconazole nanoparticles, European Journal of Pharmaceutics and Biopharmaceutics 63 (2), 95-102, 2006.
225. McConville, J. T., Overhoff, K. A., Sinswat, P., Vaughn, J. M., Frei, B. L., Burgess, D. S., Talbert, R. L., Peters, J. I., Johnston, K. P., and Williams, R. O., Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model, Pharmaceutical Research 23 (5), 901-911, 2006.